For US Healthcare Professionals Only

Make DORIBAX® your carbapenem for in vitro* potency against
P aeruginosa

CAPITAL Program: Low MICs against P aeruginosa isolates of concern*†1

CAPITAL Program: Low MICs against P aeruginosa isolates of concern

The CAPITAL (Carbapenem Antimicrobials Pseudomonas Isolate Testing At regional Locations) program, a surveillance study sponsored by Janssen Pharmaceuticals, Inc., determined MIC values of antipseudomonal agents against Pseudomonas aeruginosa (6142) isolates from 214 geographically distributed clinical laboratories in the United States and Puerto Rico from June 2009 to November 2009.1

Percent of isolates with MICs ≤2 µg/mL, ≤4 µg/mL, and ≤8 µg/mL1:

  • DORIBAX®—83%, 90%, and 96%, respectively
  • meropenem—80%, 85%, and 90%, respectively

*In vitro activity does not necessarily correlate with clinical results; not intended to convey comparative safety or efficacy.

† FDA susceptible breakpoint: DORIBAX®, MIC ≤2 µg/mL; meropenem,
MIC ≤4 µg/mL.2

Explore more about the Cumulative In Vitro Inhibition of P aeruginosa.

Please see Select Usage Information below.

References



 

Select Usage Information

 

  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting and modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy